lncRNA FOXD2-AS1 confers cisplatin resistance of non-small-cell lung cancer via regulation of miR185-5p–SIX1 axis

References

• Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. Jama Oncol. 2017;3(4):524–548. doi:10.1001/jamaoncol.2016.568827918777
   PubMed Web of Science ®Google Scholar
• Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;24 Suppl 6(suppl_3):vi99–vi105. doi:10.1093/annonc/mdt178
   Google Scholar
• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Springer Int Publ. 2016;893:1–19. doi:10.1007/978-3-319-24223-1_1
   Google Scholar
• Pirker R. Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. Transl Lung Cancer Res. 2014;3(5):305–310. doi:10.3978/j.issn.2218-6751.2014.09.1325806316
   PubMedGoogle Scholar
• Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2011;71(1):3–10. doi:10.1016/j.lungcan.2010.08.02220951465
   PubMed Web of Science ®Google Scholar
• Nagano T, Fraser P. No-nonsense functions for long noncoding RNAs. Cell. 2011;145(2):178–181. doi:10.1016/j.cell.2011.03.01421496640
   PubMed Web of Science ®Google Scholar
• Chen G, Wang Z, Wang D, et al. LncRNADisease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Res. 2013;41(Databaseissue):D983–D986. doi:10.1093/nar/gks109923175614
   PubMedGoogle Scholar
• Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703–719. doi:10.4161/rna.2048122664915
   PubMed Web of Science ®Google Scholar
• Fang S, Gao H, Tong Y, et al. Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells. Lab Invest. 2016;96(1):60–68. doi:10.1038/labinvest.2015.12326707824
   PubMed Web of Science ®Google Scholar
• Yang Y, Jiang C, Yang Y, et al. Silencing of LncRNA-HOTAIR decreases drug resistance of non-small cell lung cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. Biochem Biophys Res Commun. 2018;18(497):1003–1010. doi:10.1016/j.bbrc.2018.02.141
   Google Scholar
• Ballantyne MD, Mcdonald RA, Baker AH. LncRNA/microRNA interactions in the vasculature. Clin Pharmacol Ther. 2016;99(5):494–501. doi:10.1002/cpt.35526910520
   PubMed Web of Science ®Google Scholar
• Juan L, Wang G, Radovich M, et al. Potential roles of microRNAs in regulating long intergenic noncoding RNAs. Bmc Med Genomics. 2013;6(S1):S7. doi:10.1186/1755-8794-6-S1-S7
   PubMedGoogle Scholar
• Hu B, Zhang H, Wang Z, Zhang F, Wei H, Li L. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol Ther. 2017;18(12):974–983. doi:10.1080/15384047.2017.138567929020498
   PubMed Web of Science ®Google Scholar
• Wang P, Chen D, Ma H, Li Y. LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. Oncotarget Ther. 2017;10:5137–5149. doi:10.2147/OTT.S146423
   PubMed Web of Science ®Google Scholar
• Bao J, Zhou C, Zhang J, et al. Upregulation of the long noncoding RNA FOXD2-AS1 predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Biomarkers. 2017;32(1):108–112. doi:10.5301/jbm.5000240
   Google Scholar
• Zhu Y, Qiao L, Zhou Y, Ma N, Wang C, Zhou J. Long non-coding RNA FOXD2-AS1 contributes to colorectal cancer proliferation through its interaction with microRNA-185-5p. Cancer Sci. 2018;109(7):2235–2242. doi:10.1111/cas.1363229737580
   PubMed Web of Science ®Google Scholar
• Su F, He W, Chen C, et al. The long non-coding RNA FOXD2-AS1 promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1. Cell Death Dis. 2018;9(2):233. doi:10.1038/s41419-018-0275-929445134
   PubMedGoogle Scholar
• An Q, Zhou L, Xu N. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother. 2018;103:415–420. doi:10.1016/j.biopha.2018.03.13829674277
   PubMed Web of Science ®Google Scholar
• Rong L, Zhao R, Lu J. Highly expressed long non-coding RNA FOXD2-AS1 promotes non-small cell lung cancer progression via Wnt/Î2-catenin signaling. Biochem Biophys Res Commun. 2017;484(3):586–591. doi:10.1016/j.bbrc.2017.01.14128132805
   PubMed Web of Science ®Google Scholar
• Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochimica Et Biophysica Acta. 2014;1839(11):1097–1109. doi:10.1016/j.bbagrm.2014.08.01225159663
   PubMed Web of Science ®Google Scholar
• Chen G, Sun W, Hua X, Zeng W, Yang L. Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma carcinogenesis by modulating miR-363-5p/S100A1 pathway. Gene. 2018;645:76. doi:10.1016/j.gene.2017.12.02629248577
   PubMed Web of Science ®Google Scholar
• Li CY, Liang GY, Yao WZ, et al. Integrated analysis of long non-coding RNA competing interactions reveals the potential role in progression of human gastric cancer. Int J Oncol. 2016;48(5):1965–1976. doi:10.3892/ijo.2016.340726935047
   PubMed Web of Science ®Google Scholar
• Yin C, Yin C, Zhang G, et al. miR-185-5p inhibits F-actin polymerization and reverses epithelial mesenchymal transition of human breast cancer cells by modulating RAGE. Mol Med Rep. 2018;18(3):2621–2630. doi:10.3892/mmr.2018.929430015912
   PubMed Web of Science ®Google Scholar
• Sun CC, Zhang L, Li G, et al. The lncRNA PDIA3P Interacts with miR-185-5p to modulate oral squamous cell carcinoma progression by targeting cyclin D2. Mol Ther Nucleic Acids. 2017;9(C):100–110. doi:10.1016/j.omtn.2017.08.01529246288
   PubMedGoogle Scholar
• Tan B, Li Y, Zhao Q, Fan L, Wang D. ZNF139 increases multidrug resistance in gastric cancer cells by inhibitingmiR-185. Bioscience Rep. 2018;38(5):BSR20181023. doi:10.1042/BSR20181023
   PubMedGoogle Scholar
• Pei K, Zhu JJ, Wang CE, Xie QL, Guo JY. MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. European Rev Med Pharmacol Sci. 2016;20(22):4697–4704.27906433
   PubMed Web of Science ®Google Scholar
• Tan J, Zhang C, Qian J. Expression and significance of Six1 and Ezrin in cervical cancer tissue. Tumor Biol. 2011;32(6):1241–1247. doi:10.1007/s13277-011-0228-8
   PubMedGoogle Scholar
• Kearns S, Menke C, Thorburn J, Behbakht K, Thorburn A. Abstract #5141: six1 mediated TRAIL induced apoptosis resistance in ovarian cancer. Semin Cancer Biol. 2012;22(3):187–193.22774232
   PubMedGoogle Scholar
• Wang CA, Jedlicka P, Patrick AN, et al. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. J Clin Invest. 2012;122(5):1895–1906. doi:10.1172/JCI5985822466647
   PubMed Web of Science ®Google Scholar
• Li Z, Tian T, Lv F, et al. Six1 promotes proliferation of pancreatic cancer cells via upregulation of cyclin D1 expression. Plos One. 2013;8(3):e59203. doi:10.1371/journal.pone.005920323527134
   PubMed Web of Science ®Google Scholar
• Xu H, Zhang Y, Peña MM, Pirisi L, Creek KE. Six1 promotes colorectal cancer growth and metastasis by stimulating angiogenesis and recruiting tumor-associated macrophages. Carcinogenesis. 2017;38(3):281–292. doi:10.1093/carcin/bgw12128199476
   PubMed Web of Science ®Google Scholar
• Li Z, Tian T, Hu X, et al. Six1 mediates resistance to paclitaxel in breast cancer cells. Biochem Biophys Res Commun. 2013;441(3):538–543. doi:10.1016/j.bbrc.2013.10.13124184484
   PubMed Web of Science ®Google Scholar
• Li B, Zhao S, Geng R, Huo Z, Zhang H. The sineoculis homeobox homolog 1 (SIX1) gene regulates paclitaxel resistance by affecting reactive oxygen species and autophagy in human hepatocellular carcinoma cell line HepG2. Med Sci Monit. 2018;24:2271–2279.29656300
   PubMed Web of Science ®Google Scholar
• He Z, Li G, Tang L, Li Y. SIX1 overexpression predicts poor prognosis and induces radioresistance through AKT signaling in esophageal squamous cell carcinoma. Oncotarget Ther. 2017;10:1071–1079. doi:10.2147/OTT.S125330
   PubMed Web of Science ®Google Scholar